Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q1 FY2018 Earnings Presentation
11 slides from Alkem Laboratories's earnings presentation, Aug 11, 2017
Slide 1: Alkem Laboratories Ltd. Investor Presentation Q1FY18
Alkem Laboratories Ltd. Investor Presentation Q1FY18 11th August 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key highlights for the quarter
Key highlights for the quarter Below par quarter mainly due to GST led destocking in the domestic business • India Business: YoY growth during the quarter was impacted by sharp drop in inventory levels as stockist and other trade partners prepared themselves for the GST roll-out • As per AIOCD AWACs
Slide 4: Key Financial Highlights of Q1FY18 (Consolidated)
Key Financial Highlights of Q1FY18 (Consolidated) All figures in INR mn Total Revenue from Operations India sales 11,033 14,808 8,675 12,952 Q1FY17 Q1FY18 International sales 4,057 3,590 Q1FY17 Q1FY18 Q1FY17 Q1FY18
Slide 5: Key Financial Highlights of Q1FY18 (Consolidated)
Key Financial Highlights of Q1FY18 (Consolidated) All figures in INR mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 9,019 2,711 YoY Gross Profit 7,329 not comparable due to regrouping of excise duty worth Rs519.3mn 944 as part of cost of inventory. Refer 60.9% 56.6% 18.3% 7.3% note below
Slide 6: India Business – Impacted by GST led destocking
India Business – Impacted by GST led destocking India Business: Q1FY18 Sales of Rs.8,675 million (21.4% decline YoY) • India sales contributed 68.1% to total sales for Q1FY18 • GST led sharp decline in inventory levels at the stockist and other trade partners impacted the growth of the domestic busi
Slide 7: India secondary sales performance in Q1FY18
India secondary sales performance in Q1FY18 Change in Therapy Market Our Industry Therapy Area Our Rank Rank Contribution Share Growth Growth Anti-infectives 1 37% 11.0% -7.4% -2.1% Gastro Intestinal 3 19% 5.6% 3.4% 4.5% Pain / Analgesics 3 13% 5.4% 11.5% 2.8% Vitamins / Minerals / 5 9% 3.7% 6.3% 3.
Slide 8: International Business
International Business International Business: Q1FY18 Sales of Rs.4,057 million (13.0% growth YoY) US Business Other International Markets Business • US sales contributed 23.3% to total sales for Q1FY18 • Other International Market sales contributed 8.6% to total • In Q1FY18, the Company filed 2 AND
Slide 9: Consistent Strategy, Strong Execution
Consistent Strategy, Strong Execution 1 India Sales: Consolidate our leadership position in the acute segment by driving growth in our mega brands 2 India Sales: Increase our market share in the chronic segment through market share acquisition and new product introductions 3 Improve our field force
Slide 10: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on 30th June 2017 Non-Institution, 26.36% Promoter & Institution, Promoter Group, 6.65% 66.99% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bodie
Slide 11: Thank You
Thank You